Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 and Rituximab in relapsed or refractory CLL
NCT00286780Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2006
- Primary completion
- Nov 2007
- Countries
- 1
- Sponsor
- Ascenta Therapeutics
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2 trial of r-(-)-gossypol acetic acid, sponsored by Ascenta Therapeutics. Started Jan 2006; status: completed.
02
Registry description
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Beyond the preview
Go deeper on NCT00286780.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286780.